Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Mar 29

PMID 36986607

Authors

Rebecca Maher

Almudena Moreno-Borrallo

Dhruvi Jindal

Binh T Mai

Eduardo Ruiz-Hernandez

Andrew Harkin

Affiliations

Soon will be listed here.

Abstract

Nanomedicine is currently focused on the design and development of nanocarriers that enhance drug delivery to the brain to address unmet clinical needs for treating neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers are advantageous for delivery to the central nervous system (CNS) due to their safety profiles, drug-loading capacity, and controlled-release properties. Polymer and lipid-based nanoparticles (NPs) are reported to penetrate the blood-brain barrier (BBB) and have been extensively assessed in in vitro and animal models of glioblastoma, epilepsy, and neurodegenerative disease. Since approval by the Food and Drug Administration (FDA) of intranasal esketamine for treatment of major depressive disorder, intranasal administration has emerged as an attractive route to bypass the BBB for drug delivery to the CNS. NPs can be specifically designed for intranasal administration by tailoring their size and coating with mucoadhesive agents or other moieties that promote transport across the nasal mucosa. In this review, unique characteristics of polymeric and lipid-based nanocarriers desirable for drug delivery to the brain are explored in addition to their potential for drug repurposing for the treatment of CNS disorders. Progress in intranasal drug delivery using polymeric and lipid-based nanostructures for the development of treatments of various neurological diseases are also described.

Citing Articles

Palliative patients who may benefit from intranasal delivery of symptomatic drugs: a two-center observational study evaluated the administration of morphine and dexamethasone in Polish hospices.

Ingielewicz A, Brunka Z, Szczupak M, Szymczak R Support Care Cancer. 2025; 33(2):140.

PMID: 39893351 PMC: 11787208. DOI: 10.1007/s00520-025-09189-z.

Nanoformulation innovations: Revolutionizing precision in migraine therapy.

Ghasemi Narimani M, Kalalinia F, Marouzi S, Gheshlaghi S, Salmasi Z, Hashemi M Iran J Basic Med Sci. 2025; 28(1):16-30.

PMID: 39877639 PMC: 11771329. DOI: 10.22038/ijbms.2024.79824.17290.

Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment.

Ciftci F, Ozarslan A, Kantarci I, Yelkenci A, Tavukcuoglu O, Ghorbanpour M Pharmaceutics. 2025; 17(1).

PMID: 39861768 PMC: 11769154. DOI: 10.3390/pharmaceutics17010121.

Applications of polymeric nanoparticles in drug delivery for glioblastoma.

Liu S, Tan B, Wang F, Yu Y Front Pharmacol. 2025; 15():1519479.

PMID: 39834835 PMC: 11742935. DOI: 10.3389/fphar.2024.1519479.

Nanoparticle Strategies for Treating CNS Disorders: A Comprehensive Review of Drug Delivery and Theranostic Applications.

Toader C, Dumitru A, Eva L, Serban M, Covache-Busuioc R, Ciurea A Int J Mol Sci. 2025; 25(24.

PMID: 39769066 PMC: 11676454. DOI: 10.3390/ijms252413302.

References

Jin J, Bae K, Yang H, Lee S, Kim H, Kim Y . In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 2011; 22(12):2568-72. DOI: 10.1021/bc200406n. View

Patel M, Mundada V, Sawant K . Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization, characterization, cell line studies and efficacy in schizophrenia. Drug Dev Ind Pharm. 2019; 45(8):1242-1257. DOI: 10.1080/03639045.2019.1593434. View

Meng Q, Wang A, Hua H, Jiang Y, Wang Y, Mu H . Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease. Int J Nanomedicine. 2018; 13:705-718. PMC: 5798568. DOI: 10.2147/IJN.S151474. View

Mukherjee S, Ray S, Thakur R . Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2010; 71(4):349-58. PMC: 2865805. DOI: 10.4103/0250-474X.57282. View

Montenegro L, Campisi A, Sarpietro M, Carbone C, Acquaviva R, Raciti G . In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm. 2011; 37(6):737-46. DOI: 10.3109/03639045.2010.539231. View

Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A . Size, shape, charge and "stealthy" surface: Carrier properties affect the drug circulation time . Asian J Pharm Sci. 2021; 16(4):444-458. PMC: 8520042. DOI: 10.1016/j.ajps.2020.07.005. View

Bi C, Wang A, Chu Y, Liu S, Mu H, Liu W . Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment. Int J Nanomedicine. 2016; 11:6547-6559. PMC: 5153272. DOI: 10.2147/IJN.S120939. View

He C, Hu Y, Yin L, Tang C, Yin C . Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010; 31(13):3657-66. DOI: 10.1016/j.biomaterials.2010.01.065. View

Bruinsmann F, Vaz G, de Cristo Soares Alves A, Aguirre T, Pohlmann A, Guterres S . Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials. Molecules. 2019; 24(23). PMC: 6930669. DOI: 10.3390/molecules24234312. View

10.

Ahmad M, Sabri A, Anjani Q, Dominguez-Robles J, Abdul Latip N, Hamid K . Design and Development of Levodopa Loaded Polymeric Nanoparticles for Intranasal Delivery. Pharmaceuticals (Basel). 2022; 15(3). PMC: 8951268. DOI: 10.3390/ph15030370. View

11.

Pinheiro R, Coutinho A, Pinheiro M, Neves A . Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?. Int J Mol Sci. 2021; 22(21). PMC: 8584083. DOI: 10.3390/ijms222111654. View

12.

Fine J, Stroebel B, Faltesek K, Terai K, Haase L, Knutzen K . Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease. Neurosci Lett. 2019; 714:134567. DOI: 10.1016/j.neulet.2019.134567. View

13.

Jo D, Kim J, Lee T, Kim J . Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases. Nanomedicine. 2015; 11(7):1603-11. DOI: 10.1016/j.nano.2015.04.015. View

14.

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

15.

Ways T, Lau W, Khutoryanskiy V . Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers (Basel). 2019; 10(3). PMC: 6414903. DOI: 10.3390/polym10030267. View

16.

Kakkar V, Muppu S, Chopra K, Kaur I . Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm. 2013; 85(3 Pt A):339-45. DOI: 10.1016/j.ejpb.2013.02.005. View

17.

De R, Mahata M, Kim K . Structure-Based Varieties of Polymeric Nanocarriers and Influences of Their Physicochemical Properties on Drug Delivery Profiles. Adv Sci (Weinh). 2022; 9(10):e2105373. PMC: 8981462. DOI: 10.1002/advs.202105373. View

18.

Zhou Z, Chen H, Zhang K, Yang H, Liu J, Huang Q . Protective effect of nerve growth factor on neurons after traumatic brain injury. J Basic Clin Physiol Pharmacol. 2004; 14(3):217-24. DOI: 10.1515/jbcpp.2003.14.3.217. View

19.

Williams-Medina A, Deblock M, Janigro D . Models of the Blood-Brain Barrier: Tools in Translational Medicine. Front Med Technol. 2022; 2:623950. PMC: 8757867. DOI: 10.3389/fmedt.2020.623950. View

20.

Rana I, Khan N, Ansari M, Shah F, Din F, Sarwar S . Solid lipid nanoparticles-mediated enhanced antidepressant activity of duloxetine in lipopolysaccharide-induced depressive model. Colloids Surf B Biointerfaces. 2020; 194:111209. DOI: 10.1016/j.colsurfb.2020.111209. View